| 128 | |
| Summary | Gut microbes (superkingdom: Bacteria) increase Darunavir's toxicity. |
| Gut | |
| Darunavir (PubChem CID: 213039) | |
| Bacteria (Tax ID: 2) | |
| 33964992 | |
| increase toxicity | |
| Possibilities of interaction between traditional herbs and antiviral drugs that used to treat Covid when used in combinations. Traditional Chinese herbs that contain glycoside need to be hydrolyzed by glycosidase in the gut microbiota to more bioavailable and pharmacologically active aglycone like: Polydatin -- B-glucosidase ----> Resveratrol Geniposide -- B-glucosidase ----> Genipin Quercetrin -- α-rhamnosidase--->Quercetin Glycyrrhizin-- B-glucuronidase--> Glycyrrhetinic acid Antiviral drugs (lopinavir, ritonavir, chloroquine, darunavir, ribavirin, arbidol, favipiravir, oseltamivir) could change microbiota composition and its enzyme thereby, inhibiting Chinese medicine activation and leading to toxic product accumulation. Results between 1 to 4 hours of Darunavir taking aglycon part of negative control as 100% to normalize the concentration: No significant reduction in resveratrol. Darunavir reduces genipin significantly P<0.05. Darunavir reduces quercetin significantly P<0.05 by more than 70%. Darunavir reduces glycyrrhetinic acid significantly P<0.05 by 37.9%. In vitro inhibition of bacterial β-glucosidase, α-rhamnosidase and β-glucuronidase by darunavir: Darunavir shows inhibition β-glucosidase but it more significant in genipin than resveratrol though, both are marker for β-glucosidase. No inhibition effect on α-rhamnosidase β-glucuronidase was only weakly inhibited by darunavir. |
Browse Drug-Microbiome Relationship
Home